Lachlan Brown
Stock Analyst at William Blair
(2.12)
# 2,930
Out of 4,966 analysts
10
Total ratings
50%
Success rate
8.2%
Average return
Main Sectors:
Stocks Rated by Lachlan Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANH Manhattan Associates | Downgrades: Neutral | $270 → $200 | $215.44 | -7.17% | 2 | Jun 10, 2025 | |
| HROW Harrow | Initiates: Outperform | n/a | $39.00 | - | 1 | Jun 10, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Outperform | n/a | $4.08 | - | 1 | Apr 8, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | n/a | $12.21 | - | 1 | Apr 8, 2025 | |
| SNPS Synopsys | Initiates: Buy | $600 | $603.52 | -0.58% | 1 | Jan 13, 2025 | |
| CDNS Cadence Design Systems | Initiates: Buy | $350 | $350.43 | -0.12% | 1 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Outperform | n/a | $27.57 | - | 1 | Oct 16, 2024 | |
| DSGX The Descartes Systems Group | Initiates: Neutral | $90 | $99.95 | -9.95% | 1 | May 14, 2024 | |
| SPSC SPS Commerce | Initiates: Buy | $220 | $110.30 | +99.46% | 1 | May 14, 2024 |
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270 → $200
Current: $215.44
Upside: -7.17%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $39.00
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $4.08
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $12.21
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $603.52
Upside: -0.58%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $350.43
Upside: -0.12%
Apellis Pharmaceuticals
Oct 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $27.57
Upside: -
The Descartes Systems Group
May 14, 2024
Initiates: Neutral
Price Target: $90
Current: $99.95
Upside: -9.95%
SPS Commerce
May 14, 2024
Initiates: Buy
Price Target: $220
Current: $110.30
Upside: +99.46%